CY-QUANT VASP/P2Y12

    default
    Reference
    7502
    Status
    CE
    Sample
    160 µL citrated  whole blood
    Quantity
    1 à 23 tests/run
    Detection
    ELISA
    Application
    ELISA Kits
    Form

    Coated microtiter plate, PGE1, PGE1 + ADP, Lysis buffer,Washing solution, Dilution buffer, Anti-VASP-P peroxidase, TMB, Stop solution, tool to extract wells from their strips

    CY-QUANT VASP/P2Y12 kit is dedicated to the measurement of specific platelet ADP receptor (P2Y12) antagonists. VASP (Vasodilator Stimulated Phosphoprotein) is an intracellular platelet protein which is unphosphorylated at basal state. Prostaglandin E1 (PGE1) induces phosphorylation of VASP, whereas the binding of adenosine diphosphate (ADP) to P2Y12 receptors leads to dephosphorylation of VASP. Under test conditions, in the concomitant addition of ADP and PGE1, the effect of ADP dominates and leads to VASP dephosphorylation, unless the P2Y12 receptor is efficiently blocked by antiplatelet drugs targeting this receptor (such as thienopyridines). Thus, the level of VASP phosphorylation in this condition reflects the level of P2Y12 receptor inhibition.

    Date Document Name Download
    01/12/2017 Package insert CY-QUANT VASP P2Y12 DE (144.01 KB)
    EN (131.77 KB)
    ES (134.38 KB)
    FR (135.60 KB)
    IT (132.75 KB)
    PT (135.36 KB)
    01/09/2013 Flyer CY-QUANT VASP P2Y12 EN (726.86 KB)
    Author Title Year of edition Review
    Barragan P. et al
    Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity
    2010
    Thromb. Haemost
    Jakubowski J.A. et al
    Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated
    2012
    Thromb. Haemost
    Abtan J et al
    Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein
    2013
    Thromb Haemost
    Hobl E.L et al
    Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y12-inhibition after ticagrelor intake
    2013
    Cytometry
    Gaussem P et al.
    Inefficacy of Platelet Transfusion to Reverse Ticagrelor
    2015
    N Engl J Med
    Söderlund et al
    In vitro anti-platelet potency of ticagrelor in blood samples from infants and children
    2015
    Thromb Research
    Bonello L et al
    Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome
    2015
    Thromb Haemost
    Umemura K & Iwaki T.
    The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
    2016
    Clin Pharmacol Drug Dev
    Singh D. & Silakari O.
    Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity
    2017
    Bioorg. Med. Chem.
    Ding P. et al.
    Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population
    2017
    Clin Appl Thromb Hemost.
    Deharo P. et al
    Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study
    2017
    JACC Cardiovasc Interv.
    Takehiko Nagao et al
    A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial – PRASTRO-I trial
    2018
    Expert Opinion on Pharmacotherapy
    Deepak L. Bhatt et al
    Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
    2019
    The New England Journal of Medicine
    Holm M. et al
    The MOVEMENT Trial
    2019
    Journal of the American Heart Association
    Ito Y. et al
    Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats.
    2018
    International Journal of Scientific Reports
    Bonello L. et al
    Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients.
    2017
    Thrombosis Research
    Zeymer U. et al
    Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention
    2015
    JACC: Cardiovascular Interventions
    Martin A. et al.
    Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach
    2020
    Eur J Pharmacol.